Neuroplasticity in Parkinson's disease

doi:10.1007/s00702-024-02813-y

Review

. 2024 Nov;131(11):1329-1339.

doi: 10.1007/s00702-024-02813-y. Epub 2024 Aug 5.

Neuroplasticity in Parkinson's disease

Bogdan Ovidiu Popescu^{1

2}, Lucia Batzu^{3

4}, Pedro J Garcia Ruiz⁵, Delia Tulbă⁶, Elena Moro⁷, Patrick Santens^{8

9}

Affiliations

¹ Department of Clinical Neurosciences, 'Carol Davila' University of Medicine and Pharmacy Bucharest, Bucharest, Romania. bogdan.popescu@umfcd.ro.
² Laboratory of Cell Biology, Neurosciences and Experimental Myology, 'Victor Babeș' National Institute of Pathology, Bucharest, Romania. bogdan.popescu@umfcd.ro.
³ Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, The Maurice Wohl Clinical Neuroscience Institute, King's College London, London, UK.
⁴ Parkinson's Foundation Centre of Excellence, King's College Hospital, London, UK.
⁵ Department of Neurology, Fundacion Jimenez Diaz, Madrid, Spain.
⁶ Department of Clinical Neurosciences, 'Carol Davila' University of Medicine and Pharmacy Bucharest, Bucharest, Romania.
⁷ Division of Neurology, Centre Hospitalier Universitaire de Grenoble, Grenoble Alpes University, Grenoble Institute of Neuroscience, INSERM U1216, Grenoble, France.
⁸ Department of Neurology, University Hospital Ghent, Ghent, Belgium.
⁹ Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.

PMID: 39102007
PMCID: PMC11502561
DOI: 10.1007/s00702-024-02813-y

Review

Neuroplasticity in Parkinson's disease

Bogdan Ovidiu Popescu et al. J Neural Transm (Vienna). 2024 Nov.

. 2024 Nov;131(11):1329-1339.

doi: 10.1007/s00702-024-02813-y. Epub 2024 Aug 5.

Authors

Bogdan Ovidiu Popescu^{1

2}, Lucia Batzu^{3

4}, Pedro J Garcia Ruiz⁵, Delia Tulbă⁶, Elena Moro⁷, Patrick Santens^{8

9}

Affiliations

¹ Department of Clinical Neurosciences, 'Carol Davila' University of Medicine and Pharmacy Bucharest, Bucharest, Romania. bogdan.popescu@umfcd.ro.
² Laboratory of Cell Biology, Neurosciences and Experimental Myology, 'Victor Babeș' National Institute of Pathology, Bucharest, Romania. bogdan.popescu@umfcd.ro.
³ Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, The Maurice Wohl Clinical Neuroscience Institute, King's College London, London, UK.
⁴ Parkinson's Foundation Centre of Excellence, King's College Hospital, London, UK.
⁵ Department of Neurology, Fundacion Jimenez Diaz, Madrid, Spain.
⁶ Department of Clinical Neurosciences, 'Carol Davila' University of Medicine and Pharmacy Bucharest, Bucharest, Romania.
⁷ Division of Neurology, Centre Hospitalier Universitaire de Grenoble, Grenoble Alpes University, Grenoble Institute of Neuroscience, INSERM U1216, Grenoble, France.
⁸ Department of Neurology, University Hospital Ghent, Ghent, Belgium.
⁹ Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.

PMID: 39102007
PMCID: PMC11502561
DOI: 10.1007/s00702-024-02813-y

Abstract

Parkinson's disease (PD) is the second most frequent neurodegenerative disorder, affecting millions of people and rapidly increasing over the last decades. Even though there is no intervention yet to stop the neurodegenerative pathology, many efficient treatment methods are available, including for patients with advanced PD. Neuroplasticity is a fundamental property of the human brain to adapt both to external changes and internal insults and pathological processes. In this paper we examine the current knowledge and concepts concerning changes at network level, cellular level and molecular level as parts of the neuroplastic response to protein aggregation pathology, synapse loss and neuronal loss in PD. We analyse the beneficial, compensatory effects, such as augmentation of nigral neurons efficacy, as well as negative, maladaptive effects, such as levodopa-induced dyskinesia. Effects of physical activity and different treatments on neuroplasticity are considered and the opportunity of biomarkers identification and use is discussed.

Keywords: AMPA; BDNF; Biomarkers; Dopamine; NMDA; Neuroplasticity; Parkinson’s disease.

PubMed Disclaimer

Cited by

Effectiveness of Telecoaching and Music Therapy in Neurological Disorders: A Narrative Review and Proposal for a New Interventional Approach.
Leale I, Vinciguerra C, Di Stefano V, Brighina F, Battaglia G. Leale I, et al. Healthcare (Basel). 2025 Apr 4;13(7):826. doi: 10.3390/healthcare13070826. Healthcare (Basel). 2025. PMID: 40218122 Free PMC article. Review.
Lack of significant ganglioside changes in Slc17a5 heterozygous mice: Relevance to FSASD and Parkinson's disease.
Sabir MS, Hossain MS, Pollard L, Huizing M, Gahl WA, Platt FM, Malicdan MCV. Sabir MS, et al. Biochem Biophys Rep. 2025 Mar 14;42:101979. doi: 10.1016/j.bbrep.2025.101979. eCollection 2025 Jun. Biochem Biophys Rep. 2025. PMID: 40144541 Free PMC article.
Alpha synuclein and inflammaging.
Putnam GL, Maitta RW. Putnam GL, et al. Heliyon. 2025 Jan 15;11(2):e41981. doi: 10.1016/j.heliyon.2025.e41981. eCollection 2025 Jan 30. Heliyon. 2025. PMID: 39897785 Free PMC article. Review.
Rare Copy Number Variants Intersecting Parkinson's-associated Genes in a Cohort of children With Autism Spectrum Disorders.
Erbescu A, Papuc SM, Budișteanu M, Dobre M, Iliescu C, Hinescu ME, Arghir A, Neagu M. Erbescu A, et al. Neurosci Insights. 2025 Jun 4;20:26331055251334595. doi: 10.1177/26331055251334595. eCollection 2025. Neurosci Insights. 2025. PMID: 40474964 Free PMC article.
Targeting neuroplasticity: a viewpoint on a future research direction with Parkinson's disease-related fatigue.
Hao S, Zou J. Hao S, et al. Front Aging Neurosci. 2025 Mar 25;17:1503296. doi: 10.3389/fnagi.2025.1503296. eCollection 2025. Front Aging Neurosci. 2025. PMID: 40201546 Free PMC article.

See all "Cited by" articles

References

1. Agosta F, Gatti R, Sarasso E, Volonté MA, Canu E, Meani A, Sarro L, Copetti M, Cattrysse E, Kerckhofs E, Comi G, Falini A, Filippi M (2017) Brain plasticity in Parkinson’s disease with freezing of gait induced by action observation training. J Neurol 264(1):88–101. 10.1007/s00415-016-8309-7 - PubMed
1. Ahlskog JE (2011) Does vigorous exercise have a neuroprotective effect in Parkinson disease? Neurology 77(3):288–294. 10.1212/WNL.0b013e318225ab66 - PMC - PubMed
1. Ahlskog JE (2018) Aerobic exercise: evidence for a direct brain effect to slow parkinson disease progression. Mayo Clin Proc 93(3):360–372. 10.1016/j.mayocp.2017.12.015 - PubMed
1. Albin RL, Leventhal DK (2017) The missing, the short, and the long: Levodopa responses and dopamine actions. Ann Neurol 82(1):4–19. 10.1002/ana.24961 - PMC - PubMed
1. Anderson RW, Farokhniaee A, Gunalan K, Howell B, McIntyre CC (2018) Action potential initiation, propagation, and cortical invasion in the hyperdirect pathway during subthalamic deep brain stimulation. Brain Stimul 11(5):1140–1150. 10.1016/j.brs.2018.05.008 - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

1N/2023/ PN 23.16.01.02/Ministerul Cercetării şi Inovării

LinkOut - more resources

Full Text Sources
- PubMed Central
- Springer
Medical
- MedlinePlus Health Information

[1] Agosta F, Gatti R, Sarasso E, Volonté MA, Canu E, Meani A, Sarro L, Copetti M, Cattrysse E, Kerckhofs E, Comi G, Falini A, Filippi M (2017) Brain plasticity in Parkinson’s disease with freezing of gait induced by action observation training. J Neurol 264(1):88–101. 10.1007/s00415-016-8309-7 - PubMed

[2] Agosta F, Gatti R, Sarasso E, Volonté MA, Canu E, Meani A, Sarro L, Copetti M, Cattrysse E, Kerckhofs E, Comi G, Falini A, Filippi M (2017) Brain plasticity in Parkinson’s disease with freezing of gait induced by action observation training. J Neurol 264(1):88–101. 10.1007/s00415-016-8309-7 - PubMed

[3] Ahlskog JE (2011) Does vigorous exercise have a neuroprotective effect in Parkinson disease? Neurology 77(3):288–294. 10.1212/WNL.0b013e318225ab66 - PMC - PubMed

[4] Ahlskog JE (2011) Does vigorous exercise have a neuroprotective effect in Parkinson disease? Neurology 77(3):288–294. 10.1212/WNL.0b013e318225ab66 - PMC - PubMed

[5] Ahlskog JE (2018) Aerobic exercise: evidence for a direct brain effect to slow parkinson disease progression. Mayo Clin Proc 93(3):360–372. 10.1016/j.mayocp.2017.12.015 - PubMed

[6] Ahlskog JE (2018) Aerobic exercise: evidence for a direct brain effect to slow parkinson disease progression. Mayo Clin Proc 93(3):360–372. 10.1016/j.mayocp.2017.12.015 - PubMed

[7] Albin RL, Leventhal DK (2017) The missing, the short, and the long: Levodopa responses and dopamine actions. Ann Neurol 82(1):4–19. 10.1002/ana.24961 - PMC - PubMed

[8] Albin RL, Leventhal DK (2017) The missing, the short, and the long: Levodopa responses and dopamine actions. Ann Neurol 82(1):4–19. 10.1002/ana.24961 - PMC - PubMed

[9] Anderson RW, Farokhniaee A, Gunalan K, Howell B, McIntyre CC (2018) Action potential initiation, propagation, and cortical invasion in the hyperdirect pathway during subthalamic deep brain stimulation. Brain Stimul 11(5):1140–1150. 10.1016/j.brs.2018.05.008 - PMC - PubMed

[10] Anderson RW, Farokhniaee A, Gunalan K, Howell B, McIntyre CC (2018) Action potential initiation, propagation, and cortical invasion in the hyperdirect pathway during subthalamic deep brain stimulation. Brain Stimul 11(5):1140–1150. 10.1016/j.brs.2018.05.008 - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Neuroplasticity in Parkinson's disease

Affiliations

Neuroplasticity in Parkinson's disease

Authors

Affiliations

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Medical